Nouscom raises €120M Series D to fund pivotal immunotherapy trial
The Swiss biotech plans to advance its lead therapy into a global registration study targeting Lynch Syndrome.
Nouscom, a clinical-stage biotechnology developer located in Basel, closed a €120 million (about $135 million) Series D round on Oct. 19 [1]. The investment was jointly steered by M Ventures alongside Revelation Partners [1].
Other backers joining the syndicate include 5AM Ventures, Andera Partners, Angelini Ventures, Bpifrance, CDP Venture Capital, EIB, EQT Life Sciences, Indaco Venture Partners, Neva SGR, Panakes Partners, Versant Ventures, and XGEN Ventures [1]. Set up in 2015, Nouscom builds treatments designed to direct immune defenses against neoantigens [1].
Management intends to allocate the fresh equity toward conducting one worldwide, registration-enabling clinical evaluation of candidate NOUS-209 [1]. The trial will evaluate intercepting tumors in Lynch Syndrome carriers [1]. Marina Udier, chief executive officer at Nouscom, observed that "over two million LS carriers live with up to an 80% lifetime cancer risk" [1].
Questions and answers
How much capital did Nouscom secure?
Nouscom secured €120 million (about $135 million) in Series D equity funding.
Who led the investment round?
The financing was co-led by M Ventures and Revelation Partners, joined by a syndicate of twelve institutional backers.
How does the company plan to deploy the funds?
Nouscom will fund a worldwide, registration-enabling clinical evaluation of NOUS-209 for cancer interception in Lynch Syndrome carriers.
Companies & investors in this story
Sources
- 1.Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials — EU-Startups, Oct 19, 2026